☆ 4.5 Review

Has the therapeutical ceiling been reached in Crohn's disease randomized controlled trials? A systematic review and meta-analysis

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2023)

Related references

Note: Only part of the references are listed.

Article Gastroenterology & Hepatology

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's Disease

Bruce E. Sands et al.

Summary: Mirikizumab demonstrates efficacy and safety in patients with moderate-to-severe Crohn's disease. Significant endoscopic response is observed in the Mirikizumab groups compared to the placebo group at Week 12 and is sustained through Week 52. The frequency of adverse events is similar between Mirikizumab and placebo groups.

GASTROENTEROLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials

Shomron Ben-Horin et al.

Summary: Initiating biologic treatment early in the course of Crohn's disease may yield better treatment outcomes, while disease duration does not significantly impact results in ulcerative colitis.

GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Guselkumab for the Treatment of Crohn's Disease: Induction Results From the Phase 2 GALAXI-1 Study

William J. Sandborn et al.

Summary: In this study, Guselkumab demonstrated efficacy and safety in patients with moderately to severely active Crohn's disease, with all three dose regimens showing significant clinical and endoscopic improvements compared to placebo at week 12.

GASTROENTEROLOGY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Systematic Review With Meta-analysis: Safety and Effectiveness of Combining Biologics and Small Molecules in Inflammatory Bowel Disease

Quazim A. Alayo et al.

Summary: A systematic review and meta-analysis found that dual biologic therapy or small molecule combined with a biologic therapy appears to be safe and potentially effective in patients with inflammatory bowel disease, but the evidence is uncertain.

CROHNS & COLITIS 360 (2022)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Rational Combination Therapy to Overcome the Plateau of Drug Efficacy in Inflammatory Bowel Disease

Carlos Stalgis et al.

GASTROENTEROLOGY (2021)

Add to Collection

Editorial Material Gastroenterology & Hepatology

AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease

Joseph D. Feuerstein et al.

GASTROENTEROLOGY (2021)

Add to Collection

Review Gastroenterology & Hepatology

Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics

Konstantinos H. Katsanos et al.

GUT AND LIVER (2017)

Add to Collection

Article Gastroenterology & Hepatology

25th UEG Week 2017 Barcelona, Spain, October 2017 Abstracts

[Anonymous]

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2017)

Add to Collection

Review Gastroenterology & Hepatology

Biologic agents for IBD: practical insights

Silvio Danese et al.

NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)

Add to Collection

Review Gastroenterology & Hepatology

Biologics in inflammatory bowel disease: what are the data?

Justin Cote-Daigneault et al.

UNITED EUROPEAN GASTROENTEROLOGY JOURNAL (2015)

Add to Collection

Article Gastroenterology & Hepatology

Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed

Bruce E. Sands et al.

GASTROENTEROLOGY (2014)

Add to Collection

Article Gastroenterology & Hepatology

Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial

Paul Rutgeerts et al.

GASTROENTEROLOGY (2012)

Add to Collection

Article Gastroenterology & Hepatology

Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease

Mamoru Watanabe et al.

JOURNAL OF CROHNS & COLITIS (2012)

Add to Collection

Article Gastroenterology & Hepatology

Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial

William J. Sandborn et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)

Add to Collection

Review Surgery

Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement

David Moher et al.

INTERNATIONAL JOURNAL OF SURGERY (2010)

Add to Collection

Article Medicine, General & Internal

Certolizumab pegol for the treatment of Crohn's disease

William J. Sandborn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2007)

Add to Collection

Article Gastroenterology & Hepatology

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial

Jean-Frederic Colombel et al.

GASTROENTEROLOGY (2007)

Add to Collection

Article Gastroenterology & Hepatology

Infliximab plus azathioprine for steroid-dependent Crohn's disease patients:: A randomized placebo-controlled trial

M Lémann et al.

GASTROENTEROLOGY (2006)

Add to Collection

Article Gastroenterology & Hepatology

Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial

SB Hanauer et al.

GASTROENTEROLOGY (2006)

Add to Collection

Article Gastroenterology & Hepatology

A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease

S Schreiber et al.

GASTROENTEROLOGY (2005)

Add to Collection

© Peeref 2019-2024. All rights reserved.